Cardium Therapeutics today announced that it has entered into definitive agreements with three institutional and accredited investors to sell an aggregate of 17,857,143 shares of its common stock in a registered direct offering for gross proceeds of approximately $5.0 million, before deducting placement agent’s fees and estimated offering expenses.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The investors have agreed to purchase the shares of common stock for a price of $0.28 per share with no warrant coverage.  The closing of this offering is expected to occur on or about February 16, 2012, subject to the satisfaction of customary closing conditions.  The net proceeds from the offering will be used for general working capital purposes.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., acted as the exclusive placement agent for the offering.

The common stock is being offered pursuant to a shelf registration statement that was filed by Cardium Therapeutics with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on August 27, 2010.  A prospectus supplement related to the public offering was filed with the SEC on February 13, 2012.  Copies of the prospectus and accompanying prospectus supplement relating to the offering may be obtained from the SEC’s web-site at http://www.sec.gov.

Let us hear your thoughts below.